Boston Scientific (BSX - Free Report) recently launched an advanced Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic Heart Failure Diagnostic.
Notably, these devices are FDA approved for conditional use in a magnetic resonance imaging (MRI) environment and help physicians improve heart failure (HF) management through personalized care. The devices combine the company's SmartCRT Technology with EnduraLife Battery Technology. This allows physicians to customize device settings according to individual patient needs, without draining the battery or having to go through unnecessary replacement procedures.
HeartLogic Diagnostic alarms doctors about worsening HF conditions by combining data from sensors assessing heart sounds, respiration rate and volume, thoracic impedance, heart rate and activity.
All CRT-Ds in the Resonate family of devices are enabled with SmartCRT Technology. This helps physicians modify where, when and how to pace the lower chambers of the heart using the Multisite Pacing capability for multi-electrode pacing.
The company recently initiated enrolment of patients in the MANAGE-HF study to further assess HeartLogic Diagnostic. Boston Scientific recently announced positive clinical trial data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study. The study (based on 900 patients) was conducted to examine the performance of HeartLogic Diagnostic for prediction of possibilities of HFdecompensation. The study demonstrated that HeartLogic Diagnostic increases the ability to classify patients at high or low-risk of experiencing an HF event.
In the last reported second quarter, Boston Scientific’s Cardiac Rhythm Management (CRM) segment reflected a 2% year-over-year increase in sales. Meanwhile, the company has been consistently focusing on product development to strengthen its position in this niche.
According to a report by GlobalData, the heart failure market is estimated to reach a value of $11.8 billion by 2025, at a CAGR of 13.7%. Considering the huge potential of the market, we believe the latest development is strategically placed.
However, the company is facing tough competition in the global cardiac monitoring and rhythmmanagement devices market from established players like Abbott (ABT - Free Report) , Medtronic plc (MDT - Free Report) and Edwards Lifesciences Corporation (EW - Free Report) .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>